Cargando…

Similar progression of carotid intima–media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients

OBJECTIVE: To compare progression of subclinical atherosclerosis and factors promoting it in patients with SLE and controls. METHODS: Consecutive patients with SLE and age-matched, sex-matched population controls from the SLEVIC cohort were assessed at inclusion and after 7 years with standardised d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajeganova, Sofia, Gustafsson, Thomas, Lindberg, Linnea, Hafström, Ingiäld, Frostegård, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008707/
https://www.ncbi.nlm.nih.gov/pubmed/32095248
http://dx.doi.org/10.1136/lupus-2019-000362
_version_ 1783495519558959104
author Ajeganova, Sofia
Gustafsson, Thomas
Lindberg, Linnea
Hafström, Ingiäld
Frostegård, Johan
author_facet Ajeganova, Sofia
Gustafsson, Thomas
Lindberg, Linnea
Hafström, Ingiäld
Frostegård, Johan
author_sort Ajeganova, Sofia
collection PubMed
description OBJECTIVE: To compare progression of subclinical atherosclerosis and factors promoting it in patients with SLE and controls. METHODS: Consecutive patients with SLE and age-matched, sex-matched population controls from the SLEVIC cohort were assessed at inclusion and after 7 years with standardised data collection and carotid ultrasound. Effect of risk factors on carotid intima–media thickness (cIMT) progression was examined with adjusted linear mixed models. RESULTS: A total of 77 patients and 74 controls, 68% and 61% of the original cohort, completed follow-up. The patients were (mean) 47 years old, 90% were women, and controls were 51 years old, 92% women. Patients had disease duration of (mean) 11 years, mild disease activity and low severity at both assessments. Baseline cIMT did not differ between the groups. An average absolute cIMT progression was 0.009 mm/year in patients and 0.011 mm/year in controls, intergroup difference p=0.9. Of factors at inclusion, dyslipidaemia, lower levels of high-density lipoprotein (HDL) and carotid plaque in patients and controls, and higher systolic blood pressure, total cholesterol:HDL and LDL:HDL ratios and triglycerides in patients were associated with cIMT progression. Of factors at follow-up, hypertension and blood lipids in patients and HDL in controls were significantly associated with cIMT progression. History of lupus nephritis and a higher average dose of prednisolone used since diagnosis were associated with cIMT progression in patients. Associations of risk factors with cIMT progression were stronger in presence of plaques. CONCLUSION: We observed a statistically comparable progression of cIMT in patients with mild SLE and controls over 7 years, which implies that progression of subclinical atherosclerosis in some patients with SLE could follow that of the general population. Traditional cardiovascular (CV) risk factors, history of lupus nephritis and higher use of corticosteroids promote cIMT progression in SLE. Detection of carotid plaque may add to CV risk stratification.
format Online
Article
Text
id pubmed-7008707
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-70087072020-02-24 Similar progression of carotid intima–media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients Ajeganova, Sofia Gustafsson, Thomas Lindberg, Linnea Hafström, Ingiäld Frostegård, Johan Lupus Sci Med Co-Morbidities OBJECTIVE: To compare progression of subclinical atherosclerosis and factors promoting it in patients with SLE and controls. METHODS: Consecutive patients with SLE and age-matched, sex-matched population controls from the SLEVIC cohort were assessed at inclusion and after 7 years with standardised data collection and carotid ultrasound. Effect of risk factors on carotid intima–media thickness (cIMT) progression was examined with adjusted linear mixed models. RESULTS: A total of 77 patients and 74 controls, 68% and 61% of the original cohort, completed follow-up. The patients were (mean) 47 years old, 90% were women, and controls were 51 years old, 92% women. Patients had disease duration of (mean) 11 years, mild disease activity and low severity at both assessments. Baseline cIMT did not differ between the groups. An average absolute cIMT progression was 0.009 mm/year in patients and 0.011 mm/year in controls, intergroup difference p=0.9. Of factors at inclusion, dyslipidaemia, lower levels of high-density lipoprotein (HDL) and carotid plaque in patients and controls, and higher systolic blood pressure, total cholesterol:HDL and LDL:HDL ratios and triglycerides in patients were associated with cIMT progression. Of factors at follow-up, hypertension and blood lipids in patients and HDL in controls were significantly associated with cIMT progression. History of lupus nephritis and a higher average dose of prednisolone used since diagnosis were associated with cIMT progression in patients. Associations of risk factors with cIMT progression were stronger in presence of plaques. CONCLUSION: We observed a statistically comparable progression of cIMT in patients with mild SLE and controls over 7 years, which implies that progression of subclinical atherosclerosis in some patients with SLE could follow that of the general population. Traditional cardiovascular (CV) risk factors, history of lupus nephritis and higher use of corticosteroids promote cIMT progression in SLE. Detection of carotid plaque may add to CV risk stratification. BMJ Publishing Group 2020-01-09 /pmc/articles/PMC7008707/ /pubmed/32095248 http://dx.doi.org/10.1136/lupus-2019-000362 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Co-Morbidities
Ajeganova, Sofia
Gustafsson, Thomas
Lindberg, Linnea
Hafström, Ingiäld
Frostegård, Johan
Similar progression of carotid intima–media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
title Similar progression of carotid intima–media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
title_full Similar progression of carotid intima–media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
title_fullStr Similar progression of carotid intima–media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
title_full_unstemmed Similar progression of carotid intima–media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
title_short Similar progression of carotid intima–media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
title_sort similar progression of carotid intima–media thickness in 7-year surveillance of patients with mild sle and controls, but this progression is still promoted by dyslipidaemia, lower hdl levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
topic Co-Morbidities
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008707/
https://www.ncbi.nlm.nih.gov/pubmed/32095248
http://dx.doi.org/10.1136/lupus-2019-000362
work_keys_str_mv AT ajeganovasofia similarprogressionofcarotidintimamediathicknessin7yearsurveillanceofpatientswithmildsleandcontrolsbutthisprogressionisstillpromotedbydyslipidaemialowerhdllevelshypertensionhistoryoflupusnephritisandahigherprednisoloneusageinpatients
AT gustafssonthomas similarprogressionofcarotidintimamediathicknessin7yearsurveillanceofpatientswithmildsleandcontrolsbutthisprogressionisstillpromotedbydyslipidaemialowerhdllevelshypertensionhistoryoflupusnephritisandahigherprednisoloneusageinpatients
AT lindberglinnea similarprogressionofcarotidintimamediathicknessin7yearsurveillanceofpatientswithmildsleandcontrolsbutthisprogressionisstillpromotedbydyslipidaemialowerhdllevelshypertensionhistoryoflupusnephritisandahigherprednisoloneusageinpatients
AT hafstromingiald similarprogressionofcarotidintimamediathicknessin7yearsurveillanceofpatientswithmildsleandcontrolsbutthisprogressionisstillpromotedbydyslipidaemialowerhdllevelshypertensionhistoryoflupusnephritisandahigherprednisoloneusageinpatients
AT frostegardjohan similarprogressionofcarotidintimamediathicknessin7yearsurveillanceofpatientswithmildsleandcontrolsbutthisprogressionisstillpromotedbydyslipidaemialowerhdllevelshypertensionhistoryoflupusnephritisandahigherprednisoloneusageinpatients